Three preprints outlining periods of Ivermectin use. The first is a period of initial research and argumentation, then after the WHO and EMA decisions a rather emotional period which included campaigning, and later the situation evolved into almost a chaos.
The third part covering July-September 2021 includes some suggestions about changes to methodology and other practices. Immediately after the end of this period there was the molnupiravir announcement.
Part 1:Ā https://doi.org/10.13140/RG.2.2.13705.36966